Loading
Life sciences · Journal article
Natural Products and Bioprospecting · August 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a preclinical drug discovery report describing the synthesis and biological evaluation of a novel tetrahydrocurcumin derivative (C5) that shows antiproliferative activity against colorectal cancer cell lines and suppresses tumor growth in xenograft models. The compound outperformed 5-fluorouracil in cell culture (IC₅₀ 2.66 vs. higher for 5-FU) and in vivo, but these findings remain at the proof-of-concept stage and require validation in independent laboratories and clinical trials before clinical relevance can be established.
Preclinical chemical synthesis and biological screening with in vitro cell line and in vivo xenograft evaluation. In vitro: HCT116, SW480, SW620 (colorectal), HeLa (cervical), A549 (lung), HepG2 (hepatocellular) cancer cell lines. In vivo: HCT116 xenograft-bearing mice (strain, sex, age, group size not specified).. Intervention: Fluorinated tetrahydrocurcumin derivative C5 (structure and dose not explicitly stated); in vivo dose, route, and schedule not reported.. Compared with: 5-fluorouracil (5-FU) as positive control in cell lines; 5-FU also used in in vivo xenograft comparison (dose and schedule not stated)..
Fluorinated derivative C5 exhibited IC₅₀ = 2.66 ± 0.82 μM in HCT116 cells with superior activity relative to 5-FU positive control Reduced product H5 showed 13-fold potency decline (IC₅₀ = 35.74 ± 1.40 μM), confirming α,β-unsaturated carbonyl as critical pharmacophore C5 induced S-phase cell cycle arrest, triggered apoptosis via Bcl-2 modulation, and suppressed migration in HCT116 cells
In vivo comparison with 5-FU lacks randomization, blinding, and specification of efficacy and toxicity metrics Reduced product H5 showed 13-fold potency decline (IC₅₀ = 35.74 ± 1.40 μM), confirming α,β-unsaturated carbonyl as critical pharmacophore
This preclinical finding suggests C5 warrants further development as a lead compound for CRC, but clinicians should await IND-enabling toxicology, formulation work, and clinical trial data before considering for patients. The reported superiority over 5-FU is restricted to laboratory models and does not currently impact clinical practice.
Early-phase preclinical study demonstrating in vitro and xenograft efficacy of a novel compound; lacks human data, clinical outcomes, and independent replication needed to support therapeutic translation.
As stated by the source record.
Quoted from the source exactly as published.
This preclinical finding suggests C5 warrants further development as a lead compound for CRC, but clinicians should await IND-enabling toxicology, formulation work, and clinical trial data before considering for patients. The reported superiority over 5-FU is restricted to laboratory models and does not currently impact clinical practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Objective: To design and synthesize a series of tetrahydrocurcumin (THC) derivatives bearing α, β-unsaturated carbonyl moieties, evaluate their anticancer activities, screen potential candidates for colorectal cancer (CRC) therapy, and assess their biological activities. Methods: THC derivatives were synthesized in high yield via Knoevenagel condensation reaction, and their anticancer activities were evaluated in HCT116, SW480, SW620, HeLa, A549 and HepG2 cell lines. The in vitro and in vivo anti-CRC activities of the target compound were subsequently investigated. Results: Most compounds displayed potent antiproliferative activity against multiple tumor cell lines, with notably enhanced sensitivity in CRC cells. The fluorinated derivative 5 (C5) exhibited superior anti-CRC activity (IC 50 = 2.66 ± 0.82 μM) relative to the positive control 5-fluorouracil (5-FU). By contrast, its reduced product compound H5 showed a 13-fold decline in potency (IC 50 = 35.74 ± 1.40 μM), validating that the α, β-unsaturated carbonyl moiety represents the critical pharmacophore. Furthermore, C5 induced S-phase cell cycle arrest in HCT116 cells, triggered apoptosis via modulation of Bcl-2 family proteins, and suppressed cell migration. Mechanistically, it exerted its anticancer effects by inhibiting the PI3K/AKT/mTOR signaling pathway through downregulating p-AKT and p-mTOR. In vivo, C5 effectively inhibited tumor growth and cancer cell proliferation in HCT116 xenograft models, with higher efficacy and lower toxicity than 5-FU. Conclusions: These THC derivatives exhibited selective targeting toward CRC cells and suppressed the PI3K/AKT/mTOR signaling pathway, exerting significant anti-CRC efficacy both in vitro and in vivo, and thus held promise as potential lead compounds for CRC therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.